

























































Efficient bioactive oligonucleotide-protein conjugation for
cell-targeted cancer therapy
Anna Aviñó,*[a, b] Ugutz Unzueta,[b, c] María Virtudes Céspedes,[b, c] Isolda Casanova,[b, c]
Esther Vázquez,[b, d, e] Antonio Villaverde,[b, d, e] Ramon Mangues,[b, c] and Ramon Eritja*[a, b]
Oligonucleotide-protein conjugates have important applications
in biomedicine. Simple and efficient methods are described for
the preparation of these conjugates. Specifically, we describe a
new method in which a bifunctional linker is attached to thiol-
oligonucleotide to generate a reactive intermediate that is used
to link to the protein. Having similar conjugation efficacy
compared with the classical method in which the bifunctional
linker is attached first to the protein, this new approach
produces significantly more active conjugates with higher batch
to batch reproducibility. In a second approach, direct conjuga-
tion is proposed using oligonucleotides carrying carboxyl
groups. These methodologies have been applied to prepare
nanoconjugates of an engineered nanoparticle protein carrying
a T22 peptide with affinity for the CXCR4 chemokine receptor
and oligomers of the antiproliferative nucleotide 2’-deoxy-5-
fluorouridine in a very efficient way. The protocols have
potential uses for the functionalization of proteins, amino-
containing polymers or amino-lipids in order to produce
complex therapeutic nucleic acid delivery systems.
Oligonucleotide-protein conjugates hold great promise for
studying DNA-protein interactions while being versatile molec-
ular tools for biotechnology and material science.[1–3] To this
end, DNA-protein conjugates have been used to fabricate
arrangements of proteins using the specificity of base-pairing of
nucleic acids or to immobilize proteins to surfaces in the
fabrication of protein arrays or other supramolecular devices.[3–5]
Additionally, several immunological bioassays are based on the
use of these chimeras.[6]
The attachment of oligonucleotides to proteins or other
polymers have shown to enhance nucleic acids delivery in gene
inhibition strategies.[7,8] In this sense, polymer-DNA drug con-
jugates are one of the approaches to modify solubility, bio-
logical activity and stability of these drugs.[9]
Several methods have been proposed to link synthetic
oligonucleotides to proteins using both non-covalent and
covalent approaches. The reversible non-covalent strategy (e.g.
biotin-streptavidin[10] or nickel-histidine[11]) produce poorly sta-
ble conjugates with difficult handling.[7,12] A wide variety of
chemistries for covalent conjugation have been reported.[1–4]
Some of them are based on the modification at a predeter-
mined site of the oligonucleotides with reactive groups that
directly react with the amino groups of lysines or the thiol
groups of cysteines obtaining amide or disulfide bonds
respectively.[13,14] More complex strategies have also been
reported using post-transcriptional modification of the protein
or involvement of a catalytic or reactive protein domain.[15]
Since biomolecules are often present at low concentrations, the
conjugation depends on the reaction rate and the stability of
the reacting groups. More efficient results were obtained using
bioorthogonal approaches in which the reactive groups do not
modify the activity of the biomolecules. Specifically, bioorthog-
onal methods such as copper-catalyzed azide-alkyne [3+2]
cycloaddition[12] or oxime and hydrazone ligation have been
proposed.[16] In addition, several bifunctional cross-linkers have
been also described to produce protein conjugates.[17,18] The
most frequently used bifunctional linkers carry maleimide and
N-hydroxysuccinimidyl ester groups. These compounds are first
coupled with the protein to produce maleimide-protein inter-
mediates. Then, after removal of the excess of cross-linker, the
maleimide group is reacted with a thiol modified oligonucleo-
tide. However, inversion of the reactive groups has also been
described in which amino modified DNA reacts with the
biofunctional linker producing a maleimide-oligonucleotide
that finally reacts with the free thiol of cysteines of the
protein.[19]
Multifunctional proteins have emerged as powerful engi-
neered chimeric proteins that incorporate several selected
domains. Among them, protein-based nanocarriers based on
the concept of virus-mimetic vehicles have been explored for
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drug delivery.[20] Some of us have developed protein nano-
particles for targeted drug delivery to tumor cells that over-
express the chemokine receptor CXCR4. This receptor is
associated with metastatic progression in several tumor types,
including colorectal cancer and in human immunodeficiency
virus infection.[21–23] This carrier incorporates the T22 peptide, a
known ligand of CXCR4, which internalizes into CXCR4+ cells
via specific receptor endocytosis.[24,25] This engineered self-
assembling protein incorporates a green fluorescent protein
and a histidine tag.[26] The resulting T22-GFP-H6 protein nano-
particle has been reported to be an excellent drug carrier in cell
culture and for in vivo targeting to cells that overexpress the
CXCR4 receptor in metastatic colorectal cancer mouse
models.[27]
5-Fluoro-2’-deoxyuridine (FdU) is a cytotoxic drug known for
its high antitumor activity against cancer.[28] Short oligomers
carrying FdU have been described as prodrugs producing FdU
monophosphate inside the cells.[29–32] FdU monophosphate is
the active form of FdU as it can be converted to FdU
triphosphate and induce the synthesis of mutated DNA that
provoke cell death. In addition FdU monophosphate is an
inhibitor of thymidine synthase producing thymine-less cell
death. The use of short FdU oligomers for cancer treatment has
been described in the bibliography[29,32] but delivery of the
antiproliferative oligomers remains an unsolved problem.[30,31]
Our present interest is to functionalize this T22-GFP-H6 protein
nanoparticle with nucleic acid drugs for cancer treatment. To
this end, we have selected the functionalization of T22-GFP-H6
protein with oligonucleotides carrying several units of FdU
using the method based on the thiol-maleimide reaction. We
have demonstrated that this conjugate showed antitumor but
specifically antimetastatic activity in a CXCR4+ metastatic
colorectal cancer model.[33]
The classical method consists of two steps (Scheme 1A, and
supporting information S2-S8). First, T22-GFP-H6 protein is
treated with an excess of a bifunctional cross-linker 6-
Maleimidohexanoic acid N-hydroxysuccinimide ester (EMCS)
and the resulting maleimide functionalized protein is reacted
with the 3’-thiol-oligonucleotide. This two-step protocol was
efficient but time-consuming as the excess of the EMCS has to
be removed from the protein by dialysis and the maleimide
group attached to the protein can slowly react with amino
groups of Lys that contains the protein. This really was
inconvenient because we observed in some cases a low
functionalization of the protein due to the decrease of available
maleimide groups to react with the 3’-thiol-oligonucleotide and
low batch to batch reproducibility. In order to solve these
problems we studied the reversal of the order of the reactants
by reacting first the bifunctional crosslinker with the thiol-
oligonucleotide and then the resulting oligonucleotide carrying
the N-hydroxysuccinimidyl ester was used for the functionaliza-
tion of the protein (Scheme 1B and supporting information S8-
S10).
Additionally, the formation of FdU-oligonucleotide-protein
conjugates was also studied via direct amide formation using
FdU oligomers carrying 5’-carboxyl groups (Scheme 1C and
supporting information S10–S12). This approach avoids the use
of bifunctional linkers.
In the present communication we show that the new
approaches B and C are feasible, simpler and able to produce
the oligonucleotide-protein conjugates with antiproliferative
activity in one-pot reaction with equal or slightly higher
efficiency. Additionally, these methods avoid the potential
cross-linking of the protein as it was observed in the first
method and, therefore, the conjugation rate could be kept
constant between the different conjugate batches. However,
although apparently similar product is obtained by all method-
ologies in terms of nanoconjugate size and drug payload,
completely different functional performance is observed for the
nanoconjugates; showing that the used conjugation method-
ology exerts high impact in resulting nanoconjugates function-
ality even though showing similar physicochemical properties.
T22-GFP-H6-(FdU)5 nanoconjugates were generated by
covalent binding of the T22-GFP-H6 nanoparticles and oligom-
ers carrying five units of FdU (5’-(FdU)5-hexaethyleneglycol-
thiol-3’). For comparison purposes the classical approach
(Scheme 1A) was also performed (see supporting information,
S2–S8). The optimal conditions for the classical two-step
approach are the use of 5 molar excess of the linker with
respect to the protein followed by an overnight treatment with
5 molar excess of thiol-oligonucleotide. These conditions
generate conjugates with an average number of around 3
oligonucleotides per protein that corresponds to 15 molecules
of the FdU drug (Table 1). These oligonucleotide/protein ratios
are considered optimal without compromising the functionality
of the protein (binding to the CXCR4 receptor and
internalization).[33] Unfortunately, using this protocol, we ob-
served batch to batch differences in terms of FdU protein
loading. To solve this problem, we studied the excess of the
linker in the coupling reaction to the protein nanoparticle. The
results, confirmed by gel electrophoresis, indicate that when we
increase the linker excess, more bands corresponding to cross-
Scheme 1. Representation of the reactions involved in the preparation of
oligonucleotide-FdU protein conjugates. (A) The classical method involving
the addition of the maleimide group to the protein and subsequent Michael
addition of thiol-oligonucleotide. (B) Inverted one-pot addition method in
which the 3’-thiol-oligonucleotide reacts with the maleimide group of the
linker and then the oligonucleotide carrying the N-hydroxysuccinyl ester
group reacts with the protein. (C) Direct method in which the 5-carboxy-
oligonucleotide is activated and then conjugated with the protein nano-
particle. Nanoparticle in-silico representation modified from (34). Reprinted
by permission of John Wiley & Sons, Inc.
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linked nanoparticles trapped into the gel well are observed.
Consequently, fewer operative nanoparticles are obtained that
may affect the subsequent FdU loading (supporting information
Figure S5). The potential side reaction of the amino groups of
lysines to maleimido groups is in agreement with the observed
instability of maleimido lysine-rich peptides described by Eritja
et al.[35]
Based on the selective reactivity of thiol-oligonucleotides
for the maleimido function[35] we decided to study the reversal
of the order of the reactants (scheme 1B). In a first trial the
thiol-oligonucleotide was mixed with ECMS in a 1 :1 molar ratio
and after 10 min of incubation time at room temperature the
reaction mixture was added to the protein T22-GFP-H6 protein
obtaining the desired protein-oligonucleotide conjugate. To our
knowledge the selective reaction of thiol-oligonucleotides to
maleimido groups in the presence of the N-hydroxysuccinimidyl
ester has not been reported. Next, we optimized the one-pot
inverted addition method in which the thiol-oligonucleotide is
reacted first with equimolar amounts of the EMCS linker (for
10 min at room temperature) and then the mixture was added
over the T22-GFP-H6 nanoparticles solution at a 1 :5 (nano-
particles: oligo-FdU) molar ratio for 2 h at room temperature
followed by an overnight incubation at 4 °C. The second step
implies the amide formation by the activated ester of the linker
functionalized oligo-FdU and the amino groups of the external
Lys of the T22-GFP-H6. Following this method we obtained an
average functionalization of up to 3 molecules of oligo-FdU per
protein depending on the conditions, which corresponds to 15
molecules of FdU (see supporting information, S8–S10).
Although the efficiency is similar using both methods, the
second is faster as no dialysis is required to remove the linker
from the oligo-FdU. Most importantly, we did not observe any
cross-linking between different proteins (Figure S10) as we saw
in the classical method (Figure S5) even at higher concentration
of the linker or the protein (2 mg/ml), which is probably due to
the reaction of lysines to a maleimido group. The best results in
the one-pot inverted method were obtained performing an
overnight conjugation at room temperature and at 2 mg/ml
protein concentration (Table 1). The analysis by mass spectrom-
etry of the dialyzed solutions after the coupling of the thiol-
oligonucleotide showed the presence of the oligonucleotide-
carboxylic acid coming from the hydrolysis of the N-hydrox-
ysuccinimidyl ester. This compound was expected because of
the use of aqueous media. Even with the potential hydrolysis of
the N-hydroxysuccinimide ester during the thiol-maleimido
reaction the yields are good if one considers that using a 5
times excess of thiol-oligonucleotide, approx. 3 molecules of
oligonucleotide are attached to the protein. This suggests that
the thiol group reacted mainly with the maleimide group of the
bifunctional linker although we cannot discard some side
reaction between thiol group and the active ester to yield a
thioester oligonucleotide dimer that slowly hydrolyze to the
oligonucleotide-carboxylic acid.
The inverted one-pot method was extended to produce
conjugates with larger proteins. We choose BSA (Bovine Serum
Albumin Fraction V, Roche). BSA has a molecular weight of ~68
KDa being twice the size the monomeric T22-GFP-H6 protein.
BSA has 59 lysine residues, of which 30–35 have exposed
primary amines that can react with the bifunctional cross-linker.
For comparison, T22-GFP-H6 contains 23 Lys residues, all of
them exposed. We have used the optimized inverted addition
protocol to produce BSA-(FdU)5 conjugates obtaining an
average of 3 molecules of oligo-(FdU)5 per protein (supporting
information, S9, S10). It is worth to mention that in the case of
BSA in spite of being a bigger protein than T22-GFP-H6 the DLS
data indicate a smaller size (7.4 nm) compared with T22-GFP-
H6. This is because T22-GFP-H6 self-assemble to produce a
larger protein nanoparticle.[33,34]
The key step in the formation of the conjugates is the
production of pure, active and sufficient activated products to
conjugate with the protein. Next, we thought it was worth
preparing an activated oligo-FdU without using bifunctional
linkers. For that, conjugates were also obtained via direct
coupling of activated COOH-oligo-FdU and the protein nano-
particle (Scheme 1C). A carboxylic group was added to the 5’-
end of the oligo-FdU, then it was activated with sulfo-NHS (N-
hydroxysulfosuccinimide) and EDC (N-(3-Dimethylaminopropyl)-
N’-ethylcarbodiimide) and, finally, it was allowed to react with
the protein. Moderate efficacy (1.2 oligo-FdU) was obtained
using the 5–10 molar excess (see supporting information, S10–
S12).
Optimization of the reaction was accomplished using 50-
fold excess of activated oligonucleotide followed by an over-
night reaction with the protein at 2 mg/ml. Using these
conditions we obtained 4.9 FdU oligonucleotide units per
protein nanoparticle using the direct method (see supporting
information). Similarly, using the same conditions, in the
inverted one-pot addition, we obtained 5.9 FdU oligonucleotide
units that was the highest ratio of oligo-FdU coupled to the
nanoparticle protein. T22-GFP-H6-FdU conjugates were used for
Table 1. Functionalization, size and antiproliferative activity (MTT assay) of the protein conjugates carrying FdU oligomers prepared in this work.
Conjugates Method Conditions Units of oligo-drug
/proteina
Size by DLS MTT (IC50) HeLa
T22-GFP-H6-FdU Classical two-step protocol 1 mg/ml, ×5 drug excess 3 FdU/protein 11–14 nm 16.22 nM
T22-GFP-H6-FdU Inverted one-pot addition 2 mg/ml, ×5 drug excess 3 FdU/protein 11–12 nm 2.08 nM
T22-GFP-H6-FdU Direct -COOH coupling 2 mg/ml, ×5 drug excess 1.2 FdU/protein 9.5–13 nm 2.84 nM
BSA-FdU Inverted one-pot addition 2 mg/ml, x 5 drug excess 3 FdU/protein 7.4 nm n.d.
T22-GFP-H6-FdU Inverted one-pot addition 2 mg/ml, ×50 drug excess 5.9 FdU/protein 11–12 nm 0.43 nM
T22-GFP-H6-FdU Direct -COOH coupling 2 mg/ml, ×50 drug excess 4.9 FdU/protein 9.5–13 nm 1.08 nM
n.d.: not determined. aAverage number of oligonucleotide units per protein measured by UV spectroscopy
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blocking CXCR4+metastatic colon cancer stem-cells.[33] Using
these conditions, concentrated conjugates were obtained that
were highly recommended for clinical testing as we reduced
the volume required for intravenous administration.
Mass spectrometry of all conjugates confirmed the addition
of oligo-FdU to the proteins (supporting information, Figur-
es S2, S6-S9). Figure 1A shows the spectrum of T22-GFP-H6
nanoparticle and T22-GFP-H6-FdU conjugate prepared using
inverted one-pot addition.
The volume size distribution of T22-GFP-H6 nanoparticles
and T22-GFP-H6-FdU conjugates was also measured by Dynam-
ic Light Scattering (Table 1 and Figure 1B). No significant
particle size differences were observed.
Antiproliferative activity of FdU-protein conjugates was
measured by MTT assays in CXCR4 overexpressing (CXCR4+)
HeLa cells (see Figure 1C and supporting information S5). The
more active FdU conjugate was the T22-GFP-H6-FdU nano-
particle conjugate prepared by inverted one-pot method and is
in accordance with the higher FdU loading (Table 1). At 5 molar
excess of drug, the conjugate prepared by inverted one-pot
addition has 8 times higher antiproliferative activity than the
classical two-step protocol, although both have the same FdU
loading. This indicates that the new method is more efficient. In
the direct method, the antiproliferative effect is more than 5
times higher than the classic method, although only 1.2 of
oligo-FdU is conjugated. In contrast, direct exposure of HeLa
cells to unconjugated oligo-FdU dramatically reduces the
observed antitumor activity (IC50=275 nM, Figure 1H, reference
[33]) since this molecule could not be concentrated in the cell
cytosol because it does not use receptor-mediated endocytosis
to enter the cell.
When we increased the excess of the oligo-FdU, the
antiproliferative activity is slightly better in inverted one-pot
addition method rather than the direct COOH coupling because
more oligo-FdU is conjugated to the nanoparticle protein.
Likewise, dose-response viability of the conjugate T22-GFP-H6-
FdU using direct method was similar and follows the same
lineal pattern as the inverted method. In both methods, the IC50
is directly proportional to the oligo-FdU conjugated, generating
nanoconjugates with similar properties (Figure 2). However, in
the classical method, the inhibitory properties not only depend
on the FdU payload but also other potential factors such as the
proportion of the cross-linking generated during the prepara-
tion of the nanoconjugate that may negatively affect their
functionality.
We have extended this knowledge to the preparation of
conjugates carrying oligonucleotide-poly-L-Lysine conjugates
and oligonucleotide-lipid conjugate (Scheme 2, supporting
information S12–S17). Poly-L-Lys is a hydrophilic cationic
molecule with a high number of potential amino reacting
groups.[36] We employed poly-Lys, average molecular weight
4200 with around 20–35 available Lys residues. Octylamine was
used as a lipid molecule and contains a single amine.
The conjugation of oligonucleotides to cationic polymers
such as poly(L-Lys) has been described to enhance oligonucleo-
tide delivery to cells,[37] to stabilize duplex and triplex
structures[38] and to allow the introduction of multiple labels.[39]
However, there are few strategies to prepare poly-L-Lys-
conjugated oligonucleotides.[37–40] These methods require sev-
eral steps and are time-consuming procedures. Here we have
Figure 1. A). Mass spectrometry of the initial T22-GFP-H6 protein (in red) and
the T22-GFP-H6-FdU conjugate (in blue). B) DLS of the T22-GFP-H6 protein
(in green) and the T22-GFP-H6-FdU conjugate (in red) using inverted one-
pot reaction. C) Dose-response representation of CXCR4+ HeLa cells
exposed to different concentration of T22-GFP-H6-FdU conjugates for 48 h,
analyzed by MTT viability assay.
Figure 2. Functional characterization of nanoconjugates. T22-GFP-H6-FdU
payload-response trend line representation. Antitumor IC50 concentration of
each sample was calculated by dose-response curves in MTT cell viability
assays upon exposure over CXCR4+ HeLa cells for 48 h. Grey dots represent
samples generated by inverted one-pot addition, blue dots represent
samples generated by direct-COOH coupling and purple dots represent
samples generated by classical two-step protocol. Note that sample from
classical two-step protocol doesn’t fit in linear regression line.
Scheme 2. Schematic representation for the preparation of lipid-oligo-FdU
conjugates and polymer-oligoFdU conjugates using the inverted addition
method.
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prepared the T5-thiol and (FdU)5-hexaethyleneglycol-thiol-3’
and applied the one-pot inverted addition of the bifunctional
linker to generate poly-(L-Lys)-oligonucleotide conjugates. Two
different conjugates were obtained, namely T5-poly-L-Lys and
(FdU)5-poly-L-Lys (see supporting information). The mass spec-
tra analysis revealed several sets of signals corresponding to
multiple oligonucleotides attached to poly-L-Lys molecules
(Figures S14-S16, Table S1). However, the major set of signals
corresponds to the 1 :1 oligonucleotide-poly-L-Lys conjugate.
Next, we applied the protocols for the synthesis of a simple
model oligonucleotide-lipid conjugate.[41] Lipids are also inter-
esting molecules used to improve the delivery of the
oligonucleotides. Here we tested our inverted addition method-
ology for the addition of n-octylamine, a hydrophobic molecule
carrying one single amino group. In this case, we obtained the
corresponding T5-octyl and (FU)5-octyl conjugates in good yield.
The simplicity of the conjugates allowed the standard reversed-
phase HPLC purification (Figure S21) and the major peak was
isolated and characterized by mass spectrometry (supporting
information, Figures S18–S19). The possibility of quantification
of the final product allows us studying the impact on the yields
of small changes in the conditions used in the first step. Going
from 10 min to 30 min incubation time does not affect the
yield, but using a 1 :2 (thiol-DNA/EMCS) molar ratio the yield of
conjugate was clearly reduced (see supporting information,
S18–S19). This indicates that it is more critical to adjust the 1 :1
molar ratio than the time of incubation of thiol-DNA with EMCS.
Conjugation of biomolecules offers the possibility of
creating new entities with improved properties. For instance,
conjugation of oligonucleotides to proteins allows the assembly
of proteins for nanostructure arrangements, biomedical diag-
nostics or for an efficient delivery of the therapeutic nucleic
acids.
Bifunctional linkers, although having appeared a long time
ago, are now frequently used to generate new reacting groups
for further coupling reactions. Several linkers with different
reacting groups, length and hydrophobicity are now commer-
cially available. Here, we explored the specific reactivity of
biofunctional linkers to generate different oligonucleotide
conjugates. In particular, we improved the coupling conditions
compared to the classical method obtaining similar conjugates
in less time; also, we demonstrated the versatility of the
inverted one-pot addition method to modulate the number of
nucleic acids derivatives attached to the proteins by changing
the reaction conditions. In addition, we have demonstrated that
the direct conjugation of the biomolecules is also possible in
good yields without the use of the bifunctional linkers. This has
been accomplished because it is possible to introduce several
types of functional groups such as carboxyl groups at different
positions of nucleic acids in a very efficient way.
In proteins, the most available reacting groups are the
amino groups from Lys and, for this reason, are often used for
the conjugation with other molecules or materials. For example,
this approach has been used for the synthesis of the antibody-
drug conjugates for cancer therapies. Similarly, our methods of
preparing protein-nucleic acids drug conjugates rely on the
reactivity of the lysines. We have used coupling conditions that
provided the expected conjugates in a reproducible and
efficient way obtaining similar drug/protein ratios. Importantly,
we have demonstrated that not only the number but also the
distribution of the drug is important in the efficacy of the
protein conjugate. The order of the reacting bifunctional linker
in the synthesis of the protein conjugates plays an important
role in the production of nanostructures. The results confirmed
that using the inverted-addition method, although we did no
increase the number of conjugated oligo-FdU, the antiprolifer-
ative effect was around eight times higher compared to
classical method. In addition, we observed a higher reproduci-
bility of the different batches of the inverted-addition compared
to classical method. Similar results were obtained using the
direct method without using bifunctional linkers. Both ap-
proaches, inverted one-pot and direct methods, produce nano-
particle conjugates with antiproliferative properties directly
proportional to the FdU payload. However, the classical
method, although similar physical properties are obtained (size
and payload), the resulting product is different regarding
functionally and much less efficient.
The proposed methodologies have also been applied to
generate oligonucleotide conjugates with lipids or poly-L-Lys,
with different number of amino reactive groups, proving their
extended applicability to different potential drug carriers. In
particular, we can envision the use of these simple and useful
methodologies to conjugate oligonucleotides to other mole-
cules of interest such as carbohydrates, peptides or antibodies.
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